中国药物警戒 ›› 2016, Vol. 13 ›› Issue (7): 389-393.

• 基础与临床研究 • 上一篇    下一篇

注射用右旋雷贝拉唑钠大鼠13周重复给药毒性研究

戴晓莉, 戴学栋, 郭峰, 胡建庭, 马玉奎   

  1. 山东省药学科学院,山东省化学药物重点实验室,山东 济南 250101
  • 收稿日期:2016-04-15 修回日期:2018-07-17 出版日期:2016-07-20 发布日期:2018-07-17
  • 通讯作者: 马玉奎,男,博士,副主任药师,新药评价。 E-mail:yukuima@sina.com
  • 作者简介:戴晓莉,女,硕士,主管药师,药物临床前安全性评价研究。
  • 基金资助:
    山东省自主创新及成果转化专项(2014ZZCX02104)。

Study on Repeated Dose Toxicity of Dexrabeprazole Sodium Injection in Rats for 13 Weeks

DAI Xiao-li, DAI Xue-dong, GUO Feng, HU Jian-ting, MA Yu-kui   

  1. New Drug Evaluation Center of Shandong Pharmaceutical Academy, Shandong Provincial Key Laboratory Of Chemical Drug, Shandong Jinan 250101, China
  • Received:2016-04-15 Revised:2018-07-17 Online:2016-07-20 Published:2018-07-17

摘要: 目的 研究SD大鼠连续静脉给予注射用右旋雷贝拉唑钠13周的毒性作用。 方法 选取SD大鼠190只, 雌性各半,分为溶媒对照组、注射用雷贝拉唑钠市售对照80 mg·kg-1组、注射用右旋雷贝拉唑钠80、20、5 mg·kg-1组及注射用雷贝拉唑钠、注射用右旋雷贝拉唑钠各剂量毒代卫星组,每天给药1次,连续给药13周,停药恢复4周。试验期间,全部动物每周称量体重和摄食量,给药13周及停药恢复4周时腹主动脉取血进行血液相关指标检测,剖检摘取脏器进行组织病理学检查;卫星组动物分别于首次和末次给药后颈静脉采血进行毒代动力学检测。结果 注射用右旋雷贝拉唑钠80、20 mg·kg-1剂量下可导致大鼠出现呼吸急促、步态不稳、俯卧不动等症状,血液中RBC、HGB、HCT含量降低、甲状腺出现小滤泡形成增多,停药4周后血液学异常指标均恢复正常,但甲状腺病理学改变未能完全恢复。结论 重复静脉注射给予注射用右旋雷贝拉唑钠80、20 mg·kg-1剂量下可导致SD大鼠红细胞相关指标可逆性改变、甲状腺病理改变。

关键词: 注射用右旋雷贝拉唑钠, 注射用雷贝拉唑钠, 重复给药毒性, 毒代动力学

Abstract: Objective To observe the toxicity damage of dexrabeprazole sodium injection in rats for 13 Weeks. Methods One hundred and ninety rats(female half)were randomly divided into vehicle control group, rabeprazole sodium injection control group, three dexrabeprazole sodium injection groups with different dosages (80, 20 and 5 mg·kg-1), in addition, rabeprazole sodium injection and dexrabeprazole sodium injection satellite group. Then the group should be given the injection once a day for 13 weeks, after that, stopped to recovery for 4 weeks. During the test, all the animals should weigh weight and food intake. When stopped injection and finishing recovery, blood taken from abdominal aorta, organ coefficient and histopathology were measured for the overall toxicity assessment. Respectively, Satellite animals were taken the blood at first and last injection for toxicokinetics. Results The rats in the dexrabeprazole sodium injection group at 80, 20 mg·kg-1 apperanced shortness of breath, unsteady gait, prone motionless and other symptoms. The levels of RBC,HGB,HCT in the dexrabeprazole sodium injection group at 80, 20 mg·kg-1 were significantly lower than those in vehicle control group at 13 weeks (P<0.05). The change of these parameters regained to normal at 4 weeks after withdrawal. The amount of small follicular in the thyroid gland increased at 13 weeks, and failed to fully recover at 4 weeks after the withdrawal. Conclusion Repeated administration of dexrabeprazole Sodium injection (80, 20 mg·kg-1) for 13 weeks could lead to abnormal indicators related erythrocyte and pathological lesions of thyroid in rats.

Key words: dexrabeprazole sodium injection, rabeprazole sodium injection, repeated dose toxicity, toxicokinetic

中图分类号: